Cardiff Oncology, Inc. CRDF R2K

Q: What is the current share price of Cardiff Oncology, Inc. (CRDF)?

As of 2026-07-14 21:23 PDT, Cardiff Oncology, Inc. (CRDF) trades at $1.31 on NasdaqCM. Its 52-week range is $1.18 to $4.45.

Q: What is the market capitalisation of CRDF?

Cardiff Oncology, Inc. (CRDF) has a market capitalisation of $89.56M on NasdaqCM.

Q: What is the P/E ratio of CRDF?

CRDF trades at a trailing price-to-earnings (P/E) ratio of -1.96. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.03.

Q: What is the return on equity (ROE) of CRDF?

CRDF has a return on equity (ROE) of -84.79%. Its return on capital employed (ROCE) is -107.63%.

Q: Is CRDF a good stock to buy?

This page provides a data-driven analysis of Cardiff Oncology, Inc. (CRDF), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.cardiffoncology.com

Company Profile ↓

$1.31

-68.28% 1Y

Mkt Cap$89.56M

P/E-1.96

P/B3.03

52W High$4.45

52W Low$1.18

Book Value$0.51

EPS (TTM)$-0.67

Company Overview

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Recent Developments

Dec 2025 Revenue of $593.00K (-13.2% YoY); net profit $-45.85M.
Trailing 12 Months Year-on-year growth — revenue -62.4%.
5-Year Trend Long-term compounding — revenue CAGR 6.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	6.62%
1 Year:	-62.40%

Stock Price Performance

1 Year:	-68.28%
6 Months:	-57.47%
3 Months:	-17.61%
1 Month:	-17.61%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 4% of range

$1.18 $4.45

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)45.63 · Neutral

Price Performance

1M-17.61%

3M-17.61%

6M-57.47%

1Y-68.28%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Trading 70.6% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-1.96

Industry PE

25.41

Forward P/E

-1.61

PEG Ratio

Book Value

$0.51

Price to Book

3.03

P/S

200.55

EV/EBITDA

-1.27

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

6.62%

Profit 5Y

Revenue (YoY)

-62.40%

Earnings (YoY)

Profitability & Returns

ROCE

-107.63%

ROE

-84.79%

ROA

-44.25%

Profit Margin

0.00%

Op Margin

Gross Margin

0.00%

EPS (Latest Qtr)

$-0.18

EPS (TTM)

$-0.67

Balance Sheet & Liquidity

Debt/Equity

1.86

Quick Ratio

3.20

Current Ratio

3.27

Debt

$646.00K

Total Assets

$49.17M

Current Assets

Working Capital

Ownership

Promoter Holding

5.91%

Chg in Prom Hold

FII / Inst Holding

32.84%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$89.56M

Total Revenue (TTM)

$525.00K

EBITDA

$-47.07M

Free Cash Flow

$-20.02M

Operating Cash Flow

$-37.42M

Shares Outstanding

68.37M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CRDF Cardiff Oncology, Inc. R2K	1.31	-1.96	$89.56M	0.00%	-107.63%	-84.79%	6.62%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2014	Sep 2014	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	62.02K	36.85K	51.69K	68.00K	43.00K	136.00K	72.00K	68.00K	86.00K	74.00K	91.00K	93.00K	83.00K	108.00K	141.00K	205.00K	163.00K	165.00K	109.00K	121.00K	120.00K	41.00K
Operating Income	-3.24M	-3.94M	-	-4.85M	-6.63M	-6.41M	-	-10.46M	-9.98M	-9.92M	-	-10.13M	-5.89M	-5.80M	-	-4.66M	-4.44M	-3.86M	-3.96M	-4.22M	-4.21M	-4.12M	-4.10M	-4.36M	-5.44M	-6.89M	-7.00M	-11.07M	-10.44M	-8.99M	-12.05M	-12.21M	-10.82M	-10.93M	-12.54M	-12.60M	-14.38M	-14.78M	-11.97M	-12.85M
Net Income	-1.08M	-5.38M	-	-7.17M	-10.18M	-2.74M	-	-10.26M	-10.20M	-10.19M	-	-10.00M	-8.05M	-4.29M	-	-4.79M	-3.75M	-3.77M	-3.90M	-4.13M	-4.14M	-4.09M	-4.12M	-4.50M	-5.18M	-6.76M	-6.91M	-10.99M	-10.44M	-8.57M	-11.22M	-11.15M	-9.73M	-10.01M	-11.78M	-11.86M	-13.43M	-13.94M	-11.26M	-12.35M
Diluted EPS	-0.17	-0.28	-0.25	-0.33	-0.41	-0.23	-0.26	-0.36	-0.34	-0.34	-0.34	-0.32	-3.12	-1.41	-0.06	-6.23	-5.27	-1.10	-1.02	-0.79	-0.71	-	-0.51	-0.19	-0.14	-0.17	-0.17	-0.25	-0.24	-0.20	-0.25	-0.25	-0.22	-0.22	-0.26	-0.25	-0.20	-0.21	-0.17	-0.18

Profit & Loss (Annual)

Figures in USD.

Metric	Jan 2001	Jan 2002	Jan 2003	Jan 2004	Jan 2005	Jan 2006	Jan 2007	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	-	257.70K	450.40K	259.25K	280.18K	312.81K	381.07K	505.40K	378.32K	244.63K	366.00K	-	386.00K	488.00K	683.00K	593.00K
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	40.29M	45.90M	49.33M	49.55M
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-2.98M	-4.85M	-10.69M	-14.95M	-25.27M	-40.15M	-25.60M	-17.05M	-16.68M	-19.09M	-	-39.90M	-45.41M	-48.65M	-48.96M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-39.67M	-45.01M	-47.71M	-48.06M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-38.70M	-41.44M	-45.43M	-45.85M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-267.60K	-524.22K	-481.61K	-383.02K	-5.37M	-7.84M	-7.13M	-4.68M	-5.17M	-2.48M	-5.45M	-2.24M	-11.57M	-11.81M	-14.33M	-27.47M	-39.20M	-24.91M	-16.46M	-16.41M	-19.31M	-	-38.70M	-41.44M	-45.43M	-45.85M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-0.89	-0.70	-0.88	-1.21	-1.37	-51.76	-8.26	-	-1.08	-	-0.89	-0.93	-0.95	-0.69
R&D Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.24M	17.40M	27.10M	-	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Jan 2000	Jan 2001	Jan 2002	Jan 2003	Jan 2004	Jan 2005	Jan 2006	Jan 2007	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	-	-	-	-	-	-	-	1.04M	11.67M	27.16M	28.90M	71.45M	43.95M	12.28M	14.17M	13.09M	134.73M	149.54M	116.19M	81.64M	97.19M	61.88M
Total Equity	27.24K	-240.36K	-719.39K	-1.20M	-1.58M	3.19M	3.48M	1.13M	-1.65M	-4.05M	-3.79M	-5.00M	-4.23M	2.17M	20.39M	8.35M	48.70M	19.77M	6.51M	10.08M	7.31M	128.16M	140.42M	106.34M	69.74M	82.95M	45.39M
Cash & Equivalents	-	-	-	-	-	-	-	-	-	-	-	58.70K	700.37K	10.82M	25.84M	27.29M	67.49M	13.92M	8.23M	11.45M	10.20M	130.98M	11.94M	16.35M	21.66M	51.47M	17.47M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	5.27M	9.50M	6.76M	20.55M	22.74M	24.18M	5.78M	4.09M	5.78M	6.57M	9.13M	9.85M	11.90M	14.24M	16.50M
Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	1.43M	730.37K	2.01M	4.49M	8.20M	7.80M	3.95M	2.92M	4.78M	6.12M	6.56M	7.81M	10.44M	13.43M	16.39M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-	-	-	-	-	-13.20M	-13.27M	-16.32M	-23.04M	-33.82M	-30.89M	-37.69M	-37.92M
Investing Cash Flow	-	-	-	-	-	-	-	22.84K	-67.62K	-211.00K	-131.45M	38.15M	36.20M	13.73M	1.34M
Financing Cash Flow	-	-	-	-	-	-	-	16.40M	12.08M	137.31M	35.45M	75.00K	0	53.78M	2.58M
Capital Expenditure	-1.53K	-274.08K	-649.78K	-363.29K	-2.24M	-823.48K	-101.10K	-5.10K	-67.62K	-211.00K	-205.00K	-1.01M	-582.00K	-80.00K	-44.00K
Free Cash Flow	-	-	-	-	-	-	-	-13.20M	-13.34M	-16.53M	-23.25M	-34.83M	-31.47M	-37.77M	-37.97M

Ratios (Annual)

Figures in %.

Metric	Jan 2001	Jan 2002	Jan 2003	Jan 2004	Jan 2005	Jan 2006	Jan 2007	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-1,155.2%	-1,076.6%	-4,123.7%	-5,334.2%	-8,079.5%	-10,534.9%	-5,064.4%	-4,507.6%	-6,817.8%	-5,214.8%	-	-10,337.3%	-9,305.7%	-7,123.1%	-8,256.3%
Net Margin %	-	-	-	-	-	-	-	-	-	-	-	-868.9%	-2,567.9%	-4,555.9%	-5,113.0%	-8,782.0%	-10,287.7%	-4,928.1%	-4,351.1%	-6,709.7%	-5,275.1%	-	-10,026.9%	-8,492.0%	-6,651.7%	-7,732.0%
ROE %	111.3%	72.9%	40.3%	24.3%	-168.3%	-225.4%	-631.5%	284.6%	127.6%	65.6%	109.1%	52.9%	-533.2%	-57.9%	-171.6%	-56.4%	-198.3%	-382.8%	-163.2%	-224.5%	-15.1%	-	-36.4%	-59.4%	-54.8%	-101.0%
ROCE %	-	-	-	-	-	-	-	-	-	-	-	762.1%	-44.3%	-42.5%	-61.2%	-40.0%	-111.0%	-306.9%	-151.6%	-200.8%	-14.8%	-	-36.8%	-63.8%	-58.1%	-107.6%

Shareholding Pattern

Insiders

5.91%

Institutions

32.84%

Public Float

34.90%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	5.82%	3.98M	$5.16M
2	Vanguard Capital Management LLC	4.18%	2.86M	$3.70M
3	Laurion Capital Management, LP	3.87%	2.65M	$3.43M
4	Pfizer Inc	3.53%	2.41M	$3.12M
5	Acorn Capital Advisors, LLC	2.58%	1.76M	$2.28M
6	Geode Capital Management, LLC	2.34%	1.60M	$2.07M
7	Franklin Resources, Inc.	1.76%	1.21M	$1.56M
8	State Street Corporation	1.74%	1.19M	$1.54M
9	BLAIR WILLIAM & CO/IL	1.35%	922.41K	$1.19M
10	FLPutnam Investment Management Company	0.87%	595.13K	$770.69K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CRDF

Google News ue, 30 Jun 2026

Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQTWg5Z214MmV5NXBIN2lhcElyNC1QczZIZkQ5emJmNzNMNm9nSXVaVENVbEgtM29JQV9SdnVTNGIxVG5OQUl2UzBxTEtCNkV2VFRBdlZWZFVodUF4RkU4ZUZyYW1zaUpoX3NJZW9aRVM4UWFQOHhoYnhIUDFhRjE5a1V1Z2U2T21icGUxOG…

Google News hu, 25 Jun 2026

CRDF Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBiNWhJZmJxeVdXRGhDaWRGU2tMQW9pR1RSalhsYTlhczlXdkZUcVN2QXNRZFd6anhNNUsycE1hamZoNTl1dnJpNE5UMW55SkE4dE8wbzBtaWkyR3hQMmRoTWp3Q3BVbkVrOUVBSW5XdmNXSlh1S2s1SkNR?oc=5" target="_blank">CRD…

Google News Mon, 22 Jun 2026

Cardiff Oncology (CRDF) director Gary W. Pace buys 30,000 shares in open market - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPSzBMbDJpXzl1dDBxeTFscjlwYlR5djRyZjJmZm9DVHFmQ0IzWkJlZmJBQjFuSHlFZ1JzRWxBWU80VGpVTDFMYjFVaERib3Y5dTR6MFY3ejhWdnhBWkxZVVEwd0NMcFFZeHY5Ni1hcDV4d2VXU2FwcEl0amtaSDNXSW0xVlVzUFpFNU9PM0…

Google News Wed, 03 Jun 2026

Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Upda - GuruFocus

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQQVE5M2lERVU2RmVEZlUxaGI4UzRqYjRIN3FmejNidnFya3hfQXFUUmt0OWJMcHZxUDUwMlgzaVVLRjFYd1hmVVF5Z29pYzFSY0plRS10VURDekNTQThBVHFtbnNZT2lDUUdlNE5JOTVXMzJJWGhCSExmOVlBNE92akZDaGQyZk5pZG9qZz…

Google News hu, 21 May 2026

Cardiff Oncology to Host Investor Webcast on June 3 for CRDF-004 Data Update in RAS-Mutated Metastatic Colorectal Cancer Trial - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxOQkZCeDJTdzRuS2pxLWpxSmNIYTROM3hlcTBjcjlYeFkyUV9HUUpJZEdMUWlCM2lpT09wUGpITXNlY0VETmtET1NGODVjN0FIRVlsX0FwTUFnVE9sTHBEcTNTdmRhbnlkOTlGV19kSkFkbUd6LWY5aThPR24taElLZWtTTzV1SFR1WFloSm…

Google News Mon, 01 Jun 2026

H.C. Wainwright cuts Cardiff Oncology stock rating on license termination - Investing.com

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNYkpqVlNNc1VHb3lRZXluX2h0TVQ2ZTZaa1dTUklFM0prUjM2Nm5CYnk2UmgzYU5CbU4tVTA5dkwwbVFEX0MtOHFZWVk5clhMenNXQ3M0UDZkbXVBQ2F2bWZiMU9BcmRqZUZtZGVJb1BheUJqRnZpWFd2bnZGdkNGcmFwdlhac0pxTVpBbV…

CRDF — Frequently Asked Questions

What is the current share price of Cardiff Oncology, Inc. (CRDF)?

As of 2026-07-14 21:23 PDT, Cardiff Oncology, Inc. (CRDF) trades at $1.31 on NasdaqCM. Its 52-week range is $1.18 to $4.45.

What is the market capitalisation of CRDF?

Cardiff Oncology, Inc. (CRDF) has a market capitalisation of $89.56M on NasdaqCM.

What is the P/E ratio of CRDF?

CRDF trades at a trailing price-to-earnings (P/E) ratio of -1.96. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.03.

What is the return on equity (ROE) of CRDF?

CRDF has a return on equity (ROE) of -84.79%. Its return on capital employed (ROCE) is -107.63%.

Is CRDF a good stock to buy?

This page provides a data-driven analysis of Cardiff Oncology, Inc. (CRDF), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Cardiff Oncology, Inc. CRDF R2K

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential? - Yahoo Finance

CRDF Forecast — Price Target — Prediction for 2027 - TradingView

Cardiff Oncology (CRDF) director Gary W. Pace buys 30,000 shares in open market - Stock Titan

Cardiff Oncology (CRDF) Faces Downgrade Amid Phase II Study Upda - GuruFocus

Cardiff Oncology to Host Investor Webcast on June 3 for CRDF-004 Data Update in RAS-Mutated Metastatic Colorectal Cancer Trial - Quiver Quantitative

H.C. Wainwright cuts Cardiff Oncology stock rating on license termination - Investing.com

CRDF — Frequently Asked Questions

What is the current share price of Cardiff Oncology, Inc. (CRDF)?

What is the market capitalisation of CRDF?

What is the P/E ratio of CRDF?

What is the return on equity (ROE) of CRDF?

Is CRDF a good stock to buy?

Explore More